Explore the full record of transactions filed by 何忠磊, Director. Officer active across 1 companies, notably 新天药业. In total, 16 reports have been published. Regulator: AMF. All data is free.
Declarations 16 total
Executives ● Sale新 新天药业 22 SZSE 2,190,500 shares
SZSE:273000000052638400 · 18 Dec 2025
Executives ● Purchase兰 兰州银行 7 SZSE 5,000 shares
SZSE:173000008572407460 · 18 Feb 2025
Ideal exit: 15 Nov 2025 (T+270) Executives ● Purchase兰 兰州银行 7 SZSE 21,000 shares
SZSE:173000008467691420 · 20 Jan 2025
Ideal exit: 17 Oct 2025 (T+270) Executives ● Purchase兰 兰州银行 7 SZSE 60,000 shares
SZSE:173000008463045280 · 17 Jan 2025
Ideal exit: 14 Oct 2025 (T+270) Executives ● Purchase兰 兰州银行 7 SZSE 10,000 shares
SZSE:173000008402299550 · 3 Jan 2025
Ideal exit: 30 Sept 2025 (T+270) Executives ● Purchase兰 兰州银行 7 SZSE 29,000 shares
SZSE:173000006275045150 · 13 Feb 2023
Ideal exit: 10 Nov 2023 (T+270) Executives ● Purchase兰 兰州银行 11 SZSE 33,100 shares
SZSE:173000006251051070 · 1 Feb 2023
Ideal exit: 29 Oct 2023 (T+270) Executives ● Sale新 新天药业 11 SZSE 12,000 shares
SZSE:173000006007403000 · 2 Nov 2022
Executives ● Sale新 新天药业 7 SZSE 3,400 shares
SZSE:173000005962873100 · 19 Oct 2022
Executives ● Sale新 新天药业 11 SZSE 46,000 shares
SZSE:173000005962890800 · 19 Oct 2022
Executives ● Sale新 新天药业 7 SZSE 19,400 shares
SZSE:173000005962873570 · 19 Oct 2022
Executives ● Sale新 新天药业 11 SZSE 8,000 shares
SZSE:173000005962873540 · 19 Oct 2022
Executives ● Sale新 新天药业 11 SZSE 16,000 shares
SZSE:173000005962873470 · 19 Oct 2022
Executives ● Sale新 新天药业 7 SZSE 252,000 shares
SZSE:173000005962873400 · 19 Oct 2022
Executives ● Sale新 新天药业 7 SZSE 3,500 shares
SZSE:173000005962873200 · 19 Oct 2022
Executives ● Purchase兰 兰州银行 7 SZSE 500 shares
SZSE:173000005339583970 · 11 Jan 2022
Ideal exit: 8 Oct 2022 (T+270) About 何忠磊 He Zhonglei is a member of the board of directors at新天药业. With significant experience in the industry, he contributes to formulating the company's strategy and making key decisions. His expertise is valuable in guiding the company towards sustainable growth and continuous improvement.